Showing 8,901 - 8,920 results of 8,962 for search 'significantly ((((((lower decrease) OR (teer decrease))) OR (we decrease))) OR (larger decrease))', query time: 0.58s Refine Results
  1. 8901

    Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  2. 8902
  3. 8903

    A review of geological characteristics and selenium enrichment in Se-bearing volcanogenic massive sulfide deposits by Wei Zhang (405)

    Published 2024
    “…Selenium occurs at low concentrations (0.05 ppm) in Earth’s crust and is critical for renewable energy technologies. Here, we have combined global Se-bearing VMS deposits to illustrate selenium occurrence, enrichment conditions, sources, and depositional environments. …”
  4. 8904
  5. 8905

    Table 1_The global burden of pediatric infective endocarditis (5–14 years): epidemiological patterns from 1990 to 2021 and projected trajectories.pdf by Ying Xiao (6517)

    Published 2025
    “…Despite advances in cardiac care and infection control, the global burden, temporal trends, and regional disparities of pediatric IE remain poorly characterized.</p>Methods<p>We conducted a comprehensive analysis of pediatric IE burden among children aged 5–14 years using the Global Burden of Disease (GBD) 2021 dataset. …”
  6. 8906

    Table 3_The global burden of pediatric infective endocarditis (5–14 years): epidemiological patterns from 1990 to 2021 and projected trajectories.pdf by Ying Xiao (6517)

    Published 2025
    “…Despite advances in cardiac care and infection control, the global burden, temporal trends, and regional disparities of pediatric IE remain poorly characterized.</p>Methods<p>We conducted a comprehensive analysis of pediatric IE burden among children aged 5–14 years using the Global Burden of Disease (GBD) 2021 dataset. …”
  7. 8907

    Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  8. 8908

    Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  9. 8909

    Image 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  10. 8910

    Data Sheet 1_hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways.doc by Yan Yu (56143)

    Published 2025
    “…Background<p>Breast cancer remains a leading cause of mortality among women worldwide, with existing therapeutic options often accompanied by significant side effects and a persistent risk of disease recurrence. …”
  11. 8911

    Table 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  12. 8912

    Image 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  13. 8913

    Table 7_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  14. 8914

    Data Sheet 1_Silicon and potassium synergistically alleviate salt stress and enhance soil fertility, nutrition, and physiology of passion fruit seedlings.pdf by Alicia Camila Zeferino da Silva (22465285)

    Published 2025
    “…Foliar nutrient concentrations improved while leaf Na<sup>+</sup> decreased. Biochemically, there was a significant increase in total chlorophyll, along with reduced proline levels. …”
  15. 8915

    Table 6_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  16. 8916

    Table 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  17. 8917

    Data Sheet 1_Extracorporeal photopheresis as induction therapy in lung transplantation for cystic fibrosis: a pilot randomized trial.docx by Ilaria Righi (10198817)

    Published 2025
    “…Exploratory endpoint analyses revealed significant decreases in pro-inflammatory cytokines, degranulating CD8<sup>+</sup> T lymphocytes, and NK cells in the treatment group. …”
  18. 8918

    Data Sheet 2_Silicon and potassium synergistically alleviate salt stress and enhance soil fertility, nutrition, and physiology of passion fruit seedlings.pdf by Alicia Camila Zeferino da Silva (22465285)

    Published 2025
    “…Foliar nutrient concentrations improved while leaf Na<sup>+</sup> decreased. Biochemically, there was a significant increase in total chlorophyll, along with reduced proline levels. …”
  19. 8919

    Table 4_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  20. 8920

    Table 3_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”